Lori J. Wirth, MD

Lori Wirth, MD, provides insight on the case of a 67-year-old woman with differentiated thyroid cancer and examines the management of radioiodine-refractory disease.

Lori J. Wirth, MD, associate professor of medicine at Harvard Medical School and medical director of the Center for Head and Neck Cancers at Massachusetts General Hospital, discusses how common RET alterations are in thyroid cancers.

Lori J. Wirth, MD, discussed the findings for a small cohort of patients with anaplastic thyroid cancer treated with an anti-PD-1 antibody.

Lori J. Wirth, MD, discusses the promising results seen so far with LOXO-292 in patients with thyroid cancer.

Lori J. Wirth, MD, discusses the role of lenvatinib in the treatment landscape of differentiated thyroid cancer and how this might evolve in the future.

Lori J. Wirth, MD, hematology/oncology, Department of Medicine, Massachusetts General Hospital, discusses the SELECT trial, which examined the effect of age and lenvatinib treatment on overall survival (OS) for patients with 131I-refractory differentiated thyroid cancer.

Lori J. Wirth, MD, discusses an open-label extension of the phase III SELECT trial, which looked at lenvatinib versus placebo for differentiated thyroid cancer.

Lori J. Wirth, MD, medical director, Center for Head and Neck Cancers, Massachusetts General Hospital, assistant professor, Harvard Medical School, discusses the side effects of lenvatinib in patients with thyroid cancer.

Lori J. Wirth, MD, medical director, Center for Head and Neck Cancers, Massachusetts General Hospital, assistant professor, Harvard Medical School, discusses areas of unmet need in the field of thyroid cancer.

Lori J. Wirth, MD, discusses the results from the phase III SELECT trial that analyzed lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid cancer. There were 6 treatment-related deaths on the study.